This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cao, Y. Articles by Kleinerman, E. S. Search for Related Content PubMed PubMed Citation Articles by Cao, Y. Articles by Kleinerman, E. S.

Osterix, a Transcription Factor for Osteoblast Differentiation, Mediates Antitumor Activity in Murine Osteosarcoma

¹ Division of Pediatrics and ² Department of Molecular Genetics, University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Eugenie S. Kleinerman, Division of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030. Phone: 713-792-8110; Fax: 713-794-5042; E-mail: ekleiner{at}mdanderson.org.

Osterix is a novel zinc finger–containing transcription factor that is essential for osteoblast differentiation and bone formation. We hypothesized that osterix might have a role in osteosarcoma tumor growth and metastasis. Northern blot analysis showed that the mRNA level of osterix was decreased in two mouse osteosarcoma cell lines compared with its level in normal mouse osteoblasts. Osterix expression was also decreased in three human osteosarcoma cell lines. Transfection of the osx gene into the mouse osteosarcoma cells inhibited tumor cell growth in vitro and in vivo and significantly reduced tumor incidence, tumor volume, and lung metastasis following intratibial injection. Osterix expression was also associated with decreased osteolysis. Using an in vitro migration assay, osterix suppressed the migration of tumor cells to lung extracts. These results suggest that osterix expression may play a role in osteosarcoma tumor growth and metastasis.

Key Words: osteosarcoma • osterix • osteolysis lesion • lung metastasis • transcription factor

This article has been cited by other articles:

				F. Silvestris, P. Cafforio, M. De Matteo, N. Calvani, M. A. Frassanito, and F. Dammacco Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells Clin. Cancer Res., October 1, 2008; 14(19): 6081 - 6091. [Abstract] [Full Text] [PDF]

				Y. Cao, S.-F. Jia, G. Chakravarty, B. de Crombrugghe, and E. S. Kleinerman The Osterix Transcription Factor Down-Regulates Interleukin-1{alpha} Expression in Mouse Osteosarcoma Cells Mol. Cancer Res., January 1, 2008; 6(1): 119 - 126. [Abstract] [Full Text] [PDF]

				Md. M. Ali, T. Yoshizawa, O. Ishibashi, A. Matsuda, M. Ikegame, J. Shimomura, H. Mera, K. Nakashima, and H. Kawashima PIASxbeta is a key regulator of osterix transcriptional activity and matrix mineralization in osteoblasts J. Cell Sci., August 1, 2007; 120(15): 2565 - 2573. [Abstract] [Full Text] [PDF]

				A. Orosco, O. Fromigue, C. Bazille, N. Entz-Werle, P. Levillain, P. J. Marie, and D. Modrowski Syndecan-2 Affects the Basal and Chemotherapy-Induced Apoptosis in Osteosarcoma Cancer Res., April 15, 2007; 67(8): 3708 - 3715. [Abstract] [Full Text] [PDF]

				X. Wang, H.-Y. Kua, Y. Hu, K. Guo, Q. Zeng, Q. Wu, H.-H. Ng, G. Karsenty, B. de Crombrugghe, J. Yeh, et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling J. Cell Biol., January 3, 2006; 172(1): 115 - 125. [Abstract] [Full Text] [PDF]